Cirius Eyes Phase III Plans In NASH With Interim Data Showing Liver, Metabolic Benefits
Phase IIb interim look shows liver enzyme reductions, signs of glycemic control and no increase in peripheral edema from baseline. Cirius expects to have final data in the second half of 2019.
You may also be interested in...
Privately held biotech plans to move insulin sensitizer into Phase III with ambitious goals of obtaining accelerated approval based on liver histology, while also trying to show long-term cardiovascular benefits.
There have been eight US biopharma IPOs in 2019, but only three are trading above their launch price – a big change from just three days ago.
Gossamer took an infrequently used path to go public during a US government shutdown that's kept the SEC from processing new offerings. Also, IPO filings (and withdrawals) and follow-on offerings continued during the shutdown, while VC deals keep up a brisk pace.